Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Asset Writedowns and Impairment (2016 - 2025)

Tandem Diabetes Care (TNDM) has disclosed Asset Writedowns and Impairment for 13 consecutive years, with $2.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 2.09% year-over-year to $2.7 million, compared with a TTM value of $9.5 million through Dec 2025, down 5.02%, and an annual FY2025 reading of $9.5 million, down 5.02% over the prior year.
  • Asset Writedowns and Impairment was $2.7 million for Q4 2025 at Tandem Diabetes Care, down from $3.2 million in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $14.1 million in Q2 2023 and bottomed at -$8.6 million in Q4 2023.
  • Average Asset Writedowns and Impairment over 5 years is $1.7 million, with a median of $1.5 million recorded in 2024.
  • Peak annual rise in Asset Writedowns and Impairment hit 6978.05% in 2023, while the deepest fall reached 568.47% in 2023.
  • Year by year, Asset Writedowns and Impairment stood at $871000.0 in 2021, then surged by 109.76% to $1.8 million in 2022, then tumbled by 568.47% to -$8.6 million in 2023, then skyrocketed by 131.28% to $2.7 million in 2024, then increased by 2.09% to $2.7 million in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for TNDM at $2.7 million in Q4 2025, $3.2 million in Q3 2025, and $2.1 million in Q2 2025.